Merck Change in Inventories 2010-2025 | MRK

Merck annual/quarterly change in inventories history and growth rate from 2010 to 2025. Change in inventories can be defined as the increase or decrease in a company's inventories for the period.
  • Merck change in inventories for the quarter ending March 31, 2025 was $0M, a 0% increase year-over-year.
  • Merck change in inventories for the twelve months ending March 31, 2025 was $-0.835B, a 2.33% increase year-over-year.
  • Merck annual change in inventories for 2024 was $-0.835B, a 2.33% increase from 2023.
  • Merck annual change in inventories for 2023 was $-0.816B, a 406.83% increase from 2022.
  • Merck annual change in inventories for 2022 was $-0.161B, a 76.11% decline from 2021.
Merck Annual Change in Inventories
(Millions of US $)
2024 $-835
2023 $-816
2022 $-161
2021 $-674
2020 $-895
2019 $-473
2018 $-911
2017 $-145
2016 $206
2015 $805
2014 $79
2013 $-365
2012 $-482
2011 $-678
2010 $1,990
2009 $1,211
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $191.265B $64.168B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $681.792B 52.28
Johnson & Johnson (JNJ) United States $366.758B 15.17
AbbVie (ABBV) United States $323.411B 17.83
Novo Nordisk (NVO) Denmark $307.845B 20.30
Roche Holding AG (RHHBY) Switzerland $250.462B 0.00
Novartis AG (NVS) Switzerland $236.317B 13.49
Pfizer (PFE) United States $131.787B 7.22
Sanofi (SNY) France $127.503B 12.56
Bayer (BAYRY) Germany $27.469B 5.59
Innoviva (INVA) United States $1.200B 12.58